Discover
TARA
Protara Therapeutics, Inc.
4.04
2 x 2.88
2 x 4.83
bid
ask
+
0.22
5.76%
2 @ 04:00 PM
3.85 -0.19 (4.70%)
| Ytd | -24.20% | |
| 1y | 44.29% |
3.77
day range
4.04
2.77
52 week range
7.82
| Open | 3.80 | Prev Close | 3.82 | Low | 3.77 | High | 4.04 | Mkt Cap | 227.07M |
| Vol | 1.39M | Avg Vol | 728.71K | EPS | -1.36 | P/E | N/A | Forward P/E | -1.61 |
| Beta | 1.79 | Short Ratio | 14.46 | Inst. Own | 51.11% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-11 | 50-d Avg | 4.64 | 200-d Avg | 5.30 | 1yr Est | 26.40 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-12 | 2024-09 | -0.5 | -0.5 | N/A | N/A |
| 2024-08-06 | 2024-06 | -0.82 | -0.45 | 0.37 | 45.12% |
| 2024-05-02 | 2024-03 | -0.99 | -0.97 | 0.02 | 2.02% |
| 2024-03-13 | 2023-12 | -1.03 | -0.9 | 0.13 | 12.62% |
| 2023-11-03 | 2023-09 | -1.1 | -0.87 | 0.23 | 20.91% |
| 2023-08-03 | 2023-06 | -0.97 | -1 | -0.03 | -3.09% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-12-06 | Guggenheim | Upgrade | Buy | Buy |
| 2024-12-06 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-11-14 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-08-12 | Oppenheimer | Upgrade | Outperform | Outperform |
| 2024-08-08 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-05-06 | HC Wainwright & Co. | Upgrade | Buy | Buy |
Profile
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy that is in Phase II clinical trial for patients receiving parenteral nutrition. The company is headquartered in New York, New York.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-01-18 | BANDARI JATHIN | Officer | 56.70K | Stock Award(Grant) |
| 2024-01-18 | FABBIO PATRICK | Chief Financial Officer | 22.00K | Stock Award(Grant) |
| 2024-01-18 | FRY HANNAH | Officer | 29.84K | Stock Award(Grant) |
| 2024-09-11 | OPALEYE MANAGEMENT, INC. | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Sale |
| 2024-08-27 | SHEFFERMAN JESSE M | Chief Executive Officer | 935.50K | Stock Gift |
| 2024-01-18 | ZUMMO JACQUELINE | Officer | 104.30K | Stock Award(Grant) |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | RA Capital Management, L.P. | 1.90M | 9.79M | 9.21% |
| 2024-09-29 | Opaleye Management Inc. | 1.68M | 8.66M | 8.15% |
| 2024-09-29 | Stempoint Capital LP | 942.86K | 4.86M | 4.57% |
| 2024-09-29 | Woodline Partners LP | 851.57K | 4.39M | 4.13% |
| 2024-09-29 | Boxer Capital, LLC | 811.63K | 4.18M | 3.93% |
| 2024-09-29 | Vanguard Group Inc | 759.61K | 3.91M | 3.68% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 616.30K | 3.17M | 2.99% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 140.67K | 724.44K | 0.68% |
| 2024-10-30 | Fidelity Extended Market Index Fund | 97.35K | 501.36K | 0.47% |
| 2024-09-29 | Bridgeway Funds Inc-Ultra Small Company Market Fund | 49.20K | 253.38K | 0.24% |
| 2024-10-30 | iShares Micro Cap ETF | 41.24K | 212.37K | 0.20% |
| 2024-10-30 | Fidelity Total Market Index Fund | 30.34K | 156.23K | 0.15% |
Split
| Split | Date |
|---|---|
| 1 : 40 | 2020-01-10 |